Inhibition of viral replication by ribozyme: mutational analysis of the site and mechanism of antiviral activity.
A controlled mutational study was used to determine the site and mechanism of the antiviral action of ribozymes that inhibit Sindbis virus replication. A hairpin ribozyme targeting G575 of the Sindbis virus genomic RNA was designed and cloned into a minimized alphavirus amplicon vector. Cells that were stably transfected with this construct expressed low levels of a constitutive transcript containing the ribozyme plus recognition sequences for Sindbis RNA replicase. Upon infection, the ribozyme transcript was amplified to high levels by the viral replicase, resulting in decreased viral production from infected ribozyme-expressing cells. Mutations were then introduced into the viral RNA target sequence to interfere with ribozyme binding, and compensatory changes were generated in the ribozyme recognition sequence. Single mutations in the virus or ribozyme decreased the efficacy of the ribozyme's inhibition of viral replication, and compensatory mutations restored it. To confirm that ribozyme-catalyzed RNA cleavage was actually needed for inhibition, we performed tests with a cell line expressing an inactivated ribozyme and with a virus containing a single nucleotide target mutation that allowed the ribozyme to bind but blocked cleavage at the recognition site. The results show that most of the antiviral activity of ribozymes is due to ribozyme-catalyzed cleavage at the targeted RNA sequence, but some additional inhibition seems to occur through an antisense mechanism.
Zhang
Zhenxi
Z
Department of Microbiology and Molecular Genetics, The University of Vermont, 95 Carrigan Dr., 220 Stafford Hall, Burlington, VT 05405, USA.
Burke
John M
JM
D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology*; D001483:Base Sequence; D002478:Cells, Cultured; D006224:Cricetinae; D008969:Molecular Sequence Data; D009690:Nucleic Acid Conformation; D017354:Point Mutation; D016337:RNA, Catalytic / Q000235:genetics / Q000378:metabolism* / Q000494:pharmacology*; D012367:RNA, Viral / Q000378:metabolism; D012324:RNA-Dependent RNA Polymerase / Q000235:genetics / Q000378:metabolism; D012845:Sindbis Virus / Q000187:drug effects* / Q000235:genetics / Q000502:physiology*; D014779:Virus Replication / Q000187:drug effects*
D000998:Antiviral Agents; D016337:RNA, Catalytic; D012367:RNA, Viral; D012324:RNA-Dependent RNA Polymerase
Biochemistry. 1999 Dec 7;38(49):16035-9
10587425
J Virol. 1999 Jul;73(7):5381-7
10364285
J Mol Biol. 2000 May 5;298(3):539-55
10772868
RNA. 2000 Apr;6(4):628-37
10786853
Nature. 2001 Apr 12;410(6830):780-6
11298439
J Mol Biol. 2001 Jun 15;309(4):893-902
11399066
EMBO J. 2001 Nov 15;20(22):6434-42
11707414
RNA. 2001 Nov;7(11):1638-51
11720292
Expert Opin Biol Ther. 2001 Mar;1(2):177-91
11727528
J Mol Med (Berl). 2001 Dec;79(12):695-706
11862313
J Biol Chem. 2002 Jul 19;277(29):25957-62
12006558
Am J Pharmacogenomics. 2003;3(2):131-44
12749730
Anticancer Res. 2003 May-Jun;23(3A):1997-2005
12894572
Proc Natl Acad Sci U S A. 1992 Nov 15;89(22):10802-6
1438280
J Virol. 1993 Nov;67(11):6439-46
8411346
Virology. 1994 Jan;198(1):381-4
8259675
J Biol Chem. 1994 Apr 15;269(15):11361-6
8157667
Microbiol Rev. 1994 Sep;58(3):491-562
7968923
Adv Exp Med Biol. 1995;380:399-404
8830515
Virology. 1996 Jun 15;220(2):361-6
8661387
Virology. 1996 Aug 15;222(2):464-9
8806532
Methods Mol Biol. 1997;74:161-9
9204431
RNA. 1997 Sep;3(9):961-73
9292496
Annu Rev Microbiol. 1997;51:565-92
9343360
Mol Cell. 1998 May;1(6):873-81
9660970
Nucleic Acids Res. 1998 Aug 1;26(15):3494-504
9671810
J Biol Chem. 1998 Sep 4;273(36):23524-33
9722591
Biochemistry. 1998 Dec 15;37(50):17629-36
9860879
Antiviral Res. 1999 May;42(1):47-57
10333142
Nat Struct Biol. 1999 Jun;6(6):544-9
10360357
Hepatology. 2000 Mar;31(3):769-76
10706571